Results 101 to 110 of about 213,494 (300)

The Cardiovascular Actions of DOPA Mediated by the Gene Product of ocular albinism 1

open access: yesJournal of Pharmacological Sciences, 2014
l-3,4-Dihydroxyphenylalanine (DOPA) is the metabolic precursor of dopamine, and the single most effective agent in the treatment of Parkinson’s disease.
Yoshio Goshima   +4 more
doaj   +1 more source

Sex Differences in Fall Frequency, Risk Factors, and Outcomes in Parkinson's Disease: A Cross‐Sectional Analysis

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Female sex is an independent fall risk factor in Parkinson's disease (PD), yet sex‐specific fall patterns remain unclear. Objectives To compare sex‐specific fall risk and outcomes across PD, prodromal alpha‐synucleinopathy (PAS), and healthy controls (HC); estimate fall frequency across PD progression; and assess how sex modifies ...
Joaquin A. Vizcarra   +197 more
wiley   +1 more source

Bilateral Ischemic Optic Neuropathy Developed under Interferon Therapy

open access: yesCase Reports in Ophthalmological Medicine, 2012
Introduction. Interferon is a glycoprotein produced by assigned cells of immune system. It has been used in many different diseases. Although flu-like syndrome, myalgia, rash, hypotension, thrombocytopenia and peripheral neuropathy due to interferon use ...
Fatih Selcukbiricik   +5 more
doaj   +1 more source

Visual Field Defect after Cardiac Surgery: The Striking Role of Interdisciplinary Collaboration

open access: yesCase Reports in Ophthalmological Medicine, 2015
Perioperative visual loss (POVL) is a potentially devastating complication that can occur following ocular or nonocular surgery. The leading causes of this disease are retinal vascular occlusions, ischemic optic neuropathies, and cortical blindness. POVL
Raffaele Nuzzi, Carlo Lavia
doaj   +1 more source

Protocol for a randomised controlled trial to estimate the effects and costs of a patient centred educational intervention in glaucoma management

open access: yesBMC Ophthalmology, 2012
Background Poor glaucoma education is thought to be a causative factor of non-adherence to glaucoma therapy. However, the multi-factorial nature of non-adherent behaviour may explain the failure of purely educational interventions to achieve significant ...
Cate Heidi   +5 more
doaj   +1 more source

Immunoglobulins are beneficial in SARS-CoV-2 vaccine-induced small fibre neuropathy even 3 years after onset

open access: yesJournal of Family Medicine and Primary Care
SARS-CoV-2 vaccination (SC2V) can be complicated by post-acute COVID-19 vaccination syndrome (PACVS). One manifestation of PACVS is small fibre neuropathy (SFN).
Josef Finsterer
doaj   +1 more source

JAK2 Variant and Parkinsonian Syndromes: Coincidence or Pathophysiological Link?

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background JAK2 variants are a hallmark of myeloproliferative neoplasms (MPNs), including polycythemia vera and essential thrombocythemia. These disorders are often associated with thrombotic and inflammatory complications. From a movement disorder perspective, chorea is a rare but well‐recognized neurological occurrence in this context ...
Elena Ardila Jurado   +5 more
wiley   +1 more source

Desenvolvimento e avaliação biofarmacêutica de sistemas coloidais como carreadores para a administração ocular do agente antitumoral 5-fluorouracil [PDF]

open access: yes, 2006
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde. Programa de Pós-graduação em FarmáciaO potencial das nanopartículas poliméricas em aumentar as oportunidades de absorção corneal após a administração tópica na ...
Reus, Márcia
core  

Observations on an Open‐Label Phase 1/2 Dopamine Gene Therapy Trial (OXB‐102/Axo‐Lenti‐PD) in People with Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Background SUNRISE‐PD was a dose‐escalating, phase 1/2 study investigating a second‐generation lentiviral vector gene therapy delivering the genes for dopamine synthesis (OXB‐102) to treat Parkinson's disease (PD). The trial was prematurely terminated due to insolvency of the sponsor.
Simon Rowe   +19 more
wiley   +1 more source

Novel Ocular Drug Delivery Systems: An Update on Microemulsions

open access: yes, 2020
Sufficient ophthalmic drug delivery is still challenging for pharmaceutical technologists, despite various scientific efforts. Several ocular drug carriers have been designed to enhance bioavailability by prolonging the drug retention time.
Okur, Neslihan Ustundag   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy